Ascendia

  MARKET NEWS

Ocuphire Pharma Announces Acquisition of Opus Genetics
Interius BioTherapeutics Doses First Patient With In Vivo Chimeric Antigen Receptor Gene Therapy for B-Cell Malignancies
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor
Aptar Awarded Federal Government Contract to Advance Novel Sterilization Technology for Medical Devices
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates 
BD & Ypsomed Collaborate to Advance Self-Injection Systems for High-Viscosity Biologics
PolTREG Launches Phase 2 Cell Therapy Trial in Children With Presymptomatic Diabetes
Rentschler Biopharma Announces Largest Single Investment at its Headquarters in Germany
Rhythm Pharmaceuticals & Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
UPM Biomedicals Launches FibGel, World’s First Injectable Nanocellulose Hydrogel for Medical Devices

  EXPERT CONTENT & RESOURCES

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

Significant growth in the drug delivery sector is predicted for many areas, with headliners including cell and gene therapies and the GLP-1 blockbusters. Small molecule-based formulations still dominate innovator pipelines, but advanced biologics are also….

Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System

Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System

Drug Development & Delivery recently interviewed Nathan Givoni, Co-Founder and CEO of Gelteq, to discuss challenges with traditional drug delivery and the company’s innovative ingestible gel platform designed for drug and nutrient delivery.

  FEATURED EDITORIAL

  COMPANY PROFILE

As a premier, independently owned CDMO with over 65 years of sterile injectable manufacturing experience, Simtra BioPharma Solutions (Simtra) offers world-class cGMP sterile fill/finish, technical expertise, quality service, and a uniquely collaborative approach.  Pharmaceutical and biotech companies partner with Simtra when they face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, or risk mitigation concerns. Click here for more.

  WHITEPAPERS & WEBINARS

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Whether you’re involved in research, development, or quality control, this webinar will equip you with the knowledge and tools you need to enhance your analytical processes and ensure success in your LNP projects.

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.

  WHITEPAPERS & WEBINARS

ProPerma™ Oral Formulation Technology

ProPerma™ Oral Formulation Technology

ProPerma™ uniquely improves both permeability and bioavailability of BCS III and BCS IV compounds by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients. Our “formulation toolbox” of excipients falls within the pharmaceutically accepted domain. Unlike other …

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 6 – Drug Delivery
November 13 – Parenteral Contract Manufacturing